﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: Epidemiology</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "Epidemiology"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.30.26364214v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.01.26364469v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.01.26363283v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.01.26364505v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.01.26364413v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.01.26364322v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.01.26364513v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.30.26364329v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.30.26364395v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.29.26364358v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.29.26364335v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.30.26364374v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.25.26363797v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.29.26364351v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.25.26364016v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.29.26364034v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.27.26364122v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.29.26364168v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.29.26364286v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.29.26364336v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.23.26363799v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.23.26363787v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.28.26364210v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.23.26363802v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.23.26363728v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.28.26363311v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.28.26364207v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.28.26364183v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.28.26364179v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.30.26364214v1?rss=1">
<title>
<![CDATA[
A WHO CNS5-Aligned Classification Framework for Population-Based Surveillance of Brain and Other Central Nervous System Tumors in the United States 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.30.26364214v1?rss=1
</link>
<description><![CDATA[
Background: The Central Brain Tumor Registry of the United States (CBTRUS) uses a histology grouping model based on the World Health Organization (WHO) to classify cancer registry records for clinically relevant statistical reporting. Methods: CBTRUS, together with its consulting neuropathologists, reviewed and aligned its histology groupings with the 2021 WHO Classification update. Obsolete histology nomenclature along with their International Classification of Diseases for Oncology 3rd edition (ICD-O-3) codes were identified, currently included histologies were reclassified as appropriate, and new codes found in 2021 WHO were incorporated. An evaluation was conducted of the frequency of histology codes affected in the reclassification process, as well as incidence and survival pre- and post- reclassification of CBTRUS Tumor Type Groupings. Results: After review of the CBTRUS grouping scheme, 205 codes were reclassified and 2 new codes were incorporated. Tumor type groups most affected were those classified as glioma. Reclassification resulted in 167,038 of 491,804 (34%) cases having a grouping reclassification or reporting change, indicating that the 2021 revision of the WHO Classification has significantly impacted the collection and reporting of primary b CNS tumors. Conclusion: This work demonstrates the need to be responsive to changes in classification and coding for statistics to reflect real-world clinical use. This will require collaboration from all parties to have the ability to reconcile clinical practices and surveillance requirements.
]]></description>
<dc:creator><![CDATA[ Price, M., Kruchko, C., Brat, D. J., Cimino, P. J., Huse, J. T., Jones, K. A., Silva Michels, F., Tihan, T., Ruhl, J., Ostrom, Q. T. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.26364214</dc:identifier>
<dc:title><![CDATA[A WHO CNS5-Aligned Classification Framework for Population-Based Surveillance of Brain and Other Central Nervous System Tumors in the United States]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.01.26364469v1?rss=1">
<title>
<![CDATA[
Growth trajectories and risk of underweight and overweight in childhood cancer patients and survivors: a longitudinal multicentre cohort study protocol 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.01.26364469v1?rss=1
</link>
<description><![CDATA[
Background: Underweight, overweight, and linear growth during and after cancer treatment can impact treatment efficacy and survival in childhood cancer patients, and long-term health in childhood cancer survivors (CCS). However, scientific evidence on the weight status and growth of CCS is limited. Previous studies have been small, focused on specific cancer types, or lacked objectively measured longitudinal data. The availability of standardized, semantically interoperable routine data from oncology clinics offers an unprecedented opportunity to investigate nutritional status across all childhood cancer types, treatment regimens, and critical time windows. Objectives: We will investigate underweight, overweight, and growth trajectories from birth to adulthood in childhood cancer patients and survivors. We will identify predictors associated with distinct growth and weight trajectories and assess the consistency of findings across European countries. Methods: The Growth study will collect routinely recorded sociodemographic, clinical, and anthropometric data from paediatric and adolescent cancer patients (aged <20 years) from Switzerland, Portugal and Slovenia, We will include patients diagnosed between 2004-2026, by linking data from the Swiss Childhood Cancer Registry (ChCR), the Swiss Childhood Cancer Survivor Study (SCCSS), the Swiss Federal Statistical Office (FSO), and oncology clinics in Switzerland. Deterministic linkage of data sources (ChCR, SCCSS, oncology clinics, and FSO) will be performed using social security numbers. We will calculate age- and sex-specific z-scores for weight, height, and BMI based on country-specific and World Health Organization growth references. Latent trajectory modelling will be applied to identify distinct growth and weight trajectories and to detect subgroups at increased risk of growth impairment. We will use logistic regression models to identify predictors of impaired growth. Results: The project was funded in 2025; first study results are expected to be published by autumn 2027. We will obtain routinely collected data from approximately 12,250 childhood cancer patients and survivors - 7,800 from Switzerland, 3,350 from Portugal, and 1,100 from Slovenia. Conclusions: The Growth study will provide insights into the nutritional status of childhood cancer patients and survivors and improve understanding of growth patterns in this population. Identifying high risk groups and tumour or treatment related factors will inform targeted surveillance strategies and early nutritional interventions.
]]></description>
<dc:creator><![CDATA[ Calvello, A. S., Annicchiarico, L., Shoman, Y., Leuenberger, L. M., Bento, M. J., Bielicki, J., Boettcher, C., Brazzola, P., Breia, P., Caldas, G., Drexler, B., Drozdov, D., Diezi, M., Jazbec, J., Joerger, M., Konrad, D., Kuehni, C. E., Lourenco, A., Saner, C., Scheinemann, K., Schilling, F., Stefanovic, M., Taveira Gomes, T., von Bueren, A. O., Waespe, N., Wicki, A., Schindera, C., Belle, F. N., Growth consortium ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.10.01.26364469</dc:identifier>
<dc:title><![CDATA[Growth trajectories and risk of underweight and overweight in childhood cancer patients and survivors: a longitudinal multicentre cohort study protocol]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.01.26363283v1?rss=1">
<title>
<![CDATA[
Large-scale modelling of β-thalassaemia carrier prevalence: geostatistical predictions and population estimates from a global evidence base 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.01.26363283v1?rss=1
</link>
<description><![CDATA[
Background Evidence on {beta}-thalassaemia carrier prevalence is fragmented across heterogeneous surveys and national summaries, leaving within-country variation and geographic concentration of carriers poorly resolved. This study characterises {beta}-thalassaemia carrier prevalence and carrier populations at high spatial resolution and identifies where additional data would most improve geographic coverage. Methods Using carrier-prevalence records curated through ITHANET, a global haemoglobinopathy resource, Bayesian geostatistical modelling generated high-resolution predictions across 25 countries. Predictions were integrated with population data to estimate national and subnational carrier numbers. Prediction uncertainty and gaps in existing survey coverage informed prioritisation of healthcare sites for additional surveys. Findings Predicted prevalence varied markedly within countries, and highest-prevalence areas did not coincide with the largest carrier populations. National mean prevalence was highest in Cyprus (12.99%), whereas India, China, and Pakistan had the largest carrier populations, together accounting for 81.21% of estimated carriers. Random five-fold cross-validation favoured a model capturing broad geographic patterns and location-specific variation. Predictive performance deteriorated when geographically clustered records were withheld together, indicating reduced reliability across larger gaps in geographic sampling and the need for additional data from poorly characterised areas. Survey prioritisation identified 183 healthcare sites across 17 countries for future carrier-prevalence surveys. Interpretation By distinguishing areas of high carrier prevalence, large carrier populations, and evidence gaps, this updatable framework provides a subnational evidence base to inform {beta}-thalassaemia prevention planning and guide future data collection, screening, and genetic counselling.
]]></description>
<dc:creator><![CDATA[ Kontopoulou, M., Utazi, C. E., Chaudhuri, S., Xenophontos, M., Leboff, C., Chatzimatthaiou, S., Orphanou, K., Lederer, C. W., Stephanou, C., Kountouris, P. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.10.01.26363283</dc:identifier>
<dc:title><![CDATA[Large-scale modelling of β-thalassaemia carrier prevalence: geostatistical predictions and population estimates from a global evidence base]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.01.26364505v1?rss=1">
<title>
<![CDATA[
Maternal Cigarette Smoking Trajectories and Risk of Low Birthweight in the United States: A Population-Based Analysis of 2023 to 2024 Natality Data 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.01.26364505v1?rss=1
</link>
<description><![CDATA[
Background: Maternal cigarette smoking is associated with adverse birth outcomes, but low birthweight may reflect preterm delivery, restricted fetal growth, or both. Contemporary evidence distinguishing smoking trajectories is limited. Objectives: To examine associations between maternal cigarette-smoking trajectories and low birthweight among U.S.-resident singleton live births in 2023 to 2024. Methods: We analyzed 5,861,166 U.S.-resident singleton live births in the 2023 to 2024 National Vital Statistics System natality files. Low birthweight was defined as birthweight <2,500 g. Trajectories were never smoking, quitting before pregnancy, quitting during pregnancy, persistent smoking, or other/intermittent smoking. Modified Poisson regression estimated adjusted risk ratios (aRRs) and 95% confidence intervals controlling for birth year and maternal, pregnancy, and infant characteristics. Results: Low-birthweight prevalence was 6.4% among never smokers, 7.7% among mothers who quit before pregnancy, 11.2% among those who quit during pregnancy, 14.6% among persistent smokers, and 10.2% among those with other/intermittent smoking. Compared with never smoking, adjusted risks were higher for quitting before pregnancy (aRR 1.06, 95% CI 1.03, 1.09), quitting during pregnancy (aRR 1.46, 95% CI 1.42, 1.51), persistent smoking (aRR 1.95, 95% CI 1.93, 1.98), and other/intermittent smoking (aRR 1.36, 95% CI 1.25, 1.49). Associations varied little by year (joint interaction P = 0.102). Conclusions: Persistent smoking showed the strongest association with low birthweight. Because the outcome combines preterm delivery and impaired fetal growth, the estimates should not be interpreted as associations with fetal growth restriction alone. Keywords Cigarette Smoking; Smoking Cessation; Pregnancy; Low Birthweight; Birthweight; United States
]]></description>
<dc:creator><![CDATA[ Onwuameze, C., Orji, G., Bate, M. A., Madu, V. O., Kaya, P., Inalegwu, J. E. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.10.01.26364505</dc:identifier>
<dc:title><![CDATA[Maternal Cigarette Smoking Trajectories and Risk of Low Birthweight in the United States: A Population-Based Analysis of 2023 to 2024 Natality Data]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1?rss=1">
<title>
<![CDATA[
Temporal Trends in Antimicrobial Resistance Among Clinically Important Pathogens in Iraq, 2021-2024: Implications for Empirical Antimicrobial Therapy 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1?rss=1
</link>
<description><![CDATA[
To characterise temporal changes in antimicrobial resistance (AMR) among clinically important bacterial pathogens in Iraq during 2021-2024 and examine their implications for empirical antimicrobial therapy and stewardship. We conducted a retrospective longitudinal analysis of aggregated national AMR surveillance data for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus. Annual resistance proportions were evaluated across clinically relevant antimicrobials. Temporal change was characterised using absolute percentage-point changes and exploratory linear regression. Resistance trajectories were interpreted in relation to empirical treatment options and antimicrobial stewardship. The analysis included 92,338 organism records: 40,496 (43.9%) E. coli, 24,621 (26.7%) S. aureus, 18,223 (19.7%) K. pneumoniae and 8,998 (9.7%) P. aeruginosa. In 2024, ceftriaxone resistance reached 82.9% in E. coli and 65.2% in K. pneumoniae, while ciprofloxacin resistance was 55.4% and 57.9%, respectively. Meropenem resistance reached 37.4% in K. pneumoniae and 62.3% in P. aeruginosa. Conversely, resistance declined for amoxicillin-clavulanate in E. coli (83.5% in 2021 to 57.2% in 2024) and piperacillin-tazobactam in P. aeruginosa (46.4% to 32.9%). Several pathogen-antimicrobial combinations showed marked year-to-year variation, and no temporal trend remained statistically significant after false discovery rate correction. Resistance to several agents central to empirical therapy remains high in Iraq, while substantial carbapenem resistance constrains reliance on carbapenem escalation when resistance to other {beta}-lactams is suspected. Heterogeneous trajectories indicate that empirical recommendations should not rely on single-year national antibiograms alone and support regular integration of national and local resistance surveillance into empirical treatment and antimicrobial stewardship strategies.
]]></description>
<dc:creator><![CDATA[ Darweesh, O., Ahmed, H., Al-Jawadi, H. K., Kheder, R. K., Alwiswasi, N. N., Hameed, S. M., Mohammed, H. F., Kurdi, A. I. B. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.26364389</dc:identifier>
<dc:title><![CDATA[Temporal Trends in Antimicrobial Resistance Among Clinically Important Pathogens in Iraq, 2021-2024: Implications for Empirical Antimicrobial Therapy]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.01.26364413v1?rss=1">
<title>
<![CDATA[
Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.01.26364413v1?rss=1
</link>
<description><![CDATA[
Background: Recombinant (RIV) and cell culture-based inactivated (ccIIV) influenza vaccines could improve seasonal influenza prevention; however, evidence is limited in how protection may differ among non-egg-based vaccines. Methods: We conducted a randomized trial of RIV versus ccIIV to compare vaccine immunogenicity in adults aged 18 to 64 years during the 2024-25 influenza season (ClinicalTrials.gov, NCT06518577). Active surveillance for influenza-like illness was conducted for six months post-vaccination and cumulative incidence of influenza by vaccine type was compared to estimate relative vaccine efficacy. Participants were tested for influenza by reverse-transcription polymerase chain reaction or rapid antigen tests. Immunogenicity was evaluated by hemagglutination inhibition (HAI), virus microneutralization (MN), and neuraminidase inhibition (NAI) assays in a subset of blood specimens collected pre-vaccination and one-month post-vaccination. Results: Among the 591 participants, 25 cases of influenza A were detected; 2.4% cumulative incidence among RIV recipients versus 6.1% among ccIIV recipients. The probability of influenza was 61% lower with RIV than ccIIV (95% confidence interval: 7 to 84). Among 151 participants, post-vaccination HAI and MN titers vaccine components were higher among RIV recipients while NAI titers were higher among ccIIV recipients. Conclusions: RIV provided better protection than ccIIV against influenza A illness in adults during the U.S. 2024-2025 season.
]]></description>
<dc:creator><![CDATA[ Sumner, K. M., Noble, E. K., Grant, L. B., Meeker, J. R., Murugan, V., Nordstrom, L., House, S. L., Presti, R., Walter, E. B., Williams, O. L., Saade, E. A., Canaday, D. H., Williams, K. V., Zimmerman, R., Gross, F. L., Valencia, S., Gurbaxani, B. M., Lewis, N. M., Li, Z.-N., Mishin, V., Gubareva, L., Zhou, B., Levine, M. Z., Flannery, B. M., Ellington, S., US Flu VE Network Collaborators ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.10.01.26364413</dc:identifier>
<dc:title><![CDATA[Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.01.26364322v1?rss=1">
<title>
<![CDATA[
NMR metabolomics for cardiovascular-kidney-metabolic risk stratification in an integrated healthcare system 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.01.26364322v1?rss=1
</link>
<description><![CDATA[
Metabolomic profiling predicts future disease in population cohorts, but its value in real-world healthcare remains uncertain. We profiled 250 nuclear magnetic resonance (NMR) biomarkers in 54,933 participants from a diverse integrated US healthcare system linked to longitudinal electronic health records, evaluating nine cardiovascular-kidney-metabolic disease endpoints. Adding NMR to standard-of-care predictors improved discrimination for nearly all endpoints, with the largest gains for type 2 diabetes, chronic kidney disease and metabolic dysfunction-associated steatotic liver disease. Beyond disease onset, NMR improved prediction of disease-specific complications and cross-organ outcomes. Gains persisted across demographic, anthropometric, and genetic-risk strata and were greatest where standard-of-care prediction was weakest. NMR-enhanced models generally preserved calibration, improved high-risk enrichment and increased decision-curve net benefit. Together, these findings support NMR metabolomics as a common approach to risk stratification across the cardiovascular-kidney-metabolic disease continuum and illustrate how NMR-enhanced risk estimates could be integrated with longitudinal clinical information.
]]></description>
<dc:creator><![CDATA[ Chacon-Barahona, J., Iribarren, C., Rana, J. S., Rinetti Vargas, G., Rowell, S., Elemento, O., Suhre, K., Absher, D., Krumsiek, J. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.10.01.26364322</dc:identifier>
<dc:title><![CDATA[NMR metabolomics for cardiovascular-kidney-metabolic risk stratification in an integrated healthcare system]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.01.26364513v1?rss=1">
<title>
<![CDATA[
Population-Based Prevalence of Overweight and Obesity in German Youth: Findings from MoMo 2.0 and Comparison with KiGGS 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.01.26364513v1?rss=1
</link>
<description><![CDATA[
Objective: Overweight and obesity in childhood and adolescence are major risk factors for health problems across the lifespan. This manuscript reports the current prevalence of overweight and obesity among children and adolescents aged 4-17years living in Germany and compares them with previous population-based results. Methods: A representative, cross-sectional sample of 4-17-year-olds was drawn following a multistage sampling process. Analyses are based on weight and height of 3,978 individuals measured in the field by trained test instructors between 2023-2025. Overweight and obesity classification was defined using age- and sex-specific body-mass-index percentiles. To allow for comparability of prevalence estimates derived from previous assessment waves and other panel studies dating back to 2005, an alignment factor was derived using an inverse probability of participation weighting approach. Together with sampling weights, the alignment factor was applied to obtain current, representative prevalence estimates of overweight and obesity. Results: The aligned, weighted prevalence of overweight and obesity was 16.1% (95%CI[14.5-17.9%]), whereas prevalence of obesity was 6.7% (95%CI [5.5-8.1%]). Age- and sex-specific prevalence rates are reported and compared to previous waves. Conclusions: The current prevalence of overweight and obesity in children and adolescents aged 4-17 years living in Germany remains stable over the past two decades.
]]></description>
<dc:creator><![CDATA[ Lazarides, C., Kuhnert, R., Schienkiewitz, A., Tschuschke, L., Klos, L., Fiedler, J., Wolbring, L., Hanssen-Doose, A., Volk, C., Niessner, C., Loss, J., Voelkle, M. C., Woll, A. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.10.01.26364513</dc:identifier>
<dc:title><![CDATA[Population-Based Prevalence of Overweight and Obesity in German Youth: Findings from MoMo 2.0 and Comparison with KiGGS]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.30.26364329v1?rss=1">
<title>
<![CDATA[
Modelling the influence of the duration of effectiveness and time taken to implement vector control interventions for vector-borne diseases. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.30.26364329v1?rss=1
</link>
<description><![CDATA[
Implementing vector control interventions against infectious diseases is operationally challenging, with delivery and population uptake taking considerable time within a community. Studies have suggested that the slow mass drug administration (MDA) of the endectocide, ivermectin, may have contributed to the lower epidemiological impact against malaria observed in recent cluster-randomised controlled trials, although evidence supporting this hypothesis is lacking. It is unclear whether interventions which have short but highly effective durations of entomological impact are more impactful than tools which kill the same number of mosquitoes but over a longer period. Transmission dynamics mathematical models can be used to explore the trade-offs between product profiles and investigate how different implementation periods could influence disease control. First, we use a simple vector-borne disease compartmental model to explore the epidemiological impact of killing the same number of mosquitoes over 10, 30 or 90 days. We find that for different mosquito-killing periods, the total number of cases averted is similar, although the observable impact may depend on when efficacy is assessed. Secondly, we adapted an existing malaria transmission model and simulated the fast and slow deployment of an effective endectocide MDA campaign in different seasonal settings. In perennial and seasonal settings and for a given coverage, slow MDA deployment averts more clinical cases of malaria than a fast synchronised distribution (completed in a single day, although the difference was modest). The benefits of the intervention depend on how well-timed a deployment is relative to the peak of the transmission season, with the efficacy of an ivermectin-like endectocide MDA being up to approximately 42% lower if started late. The work indicates that the time taken to complete MDA campaigns is unlikely to drive major differences in the effectiveness of short-lived endectocides and showcases how transmission dynamics models can be used to support epidemiological trial interpretation.
]]></description>
<dc:creator><![CDATA[ Chandradeva, N., Glover, A. C., Whittaker, C., Brewer, T., Challenger, J. D., Slater, H. C., Sherrard-Smith, E., Churcher, T. S. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.26364329</dc:identifier>
<dc:title><![CDATA[Modelling the influence of the duration of effectiveness and time taken to implement vector control interventions for vector-borne diseases.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.30.26364395v1?rss=1">
<title>
<![CDATA[
Increasing risks of recurrence following community-associated Clostridioides difficile infection in Oxfordshire 2000-2025 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.30.26364395v1?rss=1
</link>
<description><![CDATA[
Background Clostridioides difficile infections (CDI) continue to cause substantial morbidity and mortality, with increasing incidence in some countries post-COVID-19. Recurrence affects 10-20% of CDI patients: whether risk factors have changed over time is unclear, particularly post-COVID-19. Methods Using electronic health records from hospitals in Oxfordshire, UK, including results from community samples, we estimated the incidence of CDI recurrence across different calendar periods between 2000-2025. To investigate whether risk factors had changed over time, we used interaction tests within multivariable Fine-Gray regression models (modelling death as a competing risk), using backwards elimination, starting from 39 risk factors identified from the literature. Results Recurrence occurred within 1-year in 12.6%, 12.5%, 10.8% and 13.1% of CDI cases in "high virulence" 2003-2008 (n=527), "post-high virulence" 2008-2012 (n=252), "pre-pandemic" 2012-2020 (n=143) and "post-pandemic" 2020-2025 (n=110) periods respectively. The only factor with evidence of variation in its association with recurrence over time was surveillance classification (heterogeneity p=0.019; others p>0.05). Compared with hospital-onset cases, community-onset community-associated cases had increasing recurrence risks over time (subdistribution hazard ratios (SHRs)=2.05 (95% CI 1.27-3.31) in "post-pandemic" and 1.86 (1.16-2.98) in "pre-pandemic"), especially compared to the "high virulence" era of the early 2000s (SHR=0.81 (0.56-1.16)). This heterogeneity persisted after adjusting for baseline blood tests as a marker of severity (heterogeneity p=0.022). Conclusions Compared with hospital-onset hospital-associated cases, recurrence risks increased for community-onset community-associated CDI cases over time. Recurrence is a key contributor to overall CDI incidence and the underlying causes of increasing risks with community-onset community-associated cases should be explored further.
]]></description>
<dc:creator><![CDATA[ Dietz, E., Robotham, J., Wilcox, M. H., Brown, C., Hope, R., Muller-Pebody, B., Eyre, D. W., Walker, A. S. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.26364395</dc:identifier>
<dc:title><![CDATA[Increasing risks of recurrence following community-associated Clostridioides difficile infection in Oxfordshire 2000-2025]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.29.26364358v1?rss=1">
<title>
<![CDATA[
Design and outcome-model estimability in doubly robust survival analysis: a breast cancer reanalysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.29.26364358v1?rss=1
</link>
<description><![CDATA[
Doubly robust survival estimators require nuisance models that the available information can support. We examine design and estimator dependence in TCGA breast cancer data. Treatment indicators disagree for 337 of 1076 patients; 67.4% have unobserved five-year binary outcomes; and receptor imputation expands the triple-negative subgroup from 156 directly measured patients to 226. We compare chemotherapy initiation by day 90 with non-initiation, using adjusted restricted mean survival time (RMST) over the next 1095 days. Weighting-only estimates are 55 days (95% bootstrap interval: -24, 133) in triple- negative disease (16 deaths) and 38 days (12, 72) in the whole cohort (72 deaths). A Cox outcome-model benchmark yields 108 and 35 days, respectively, demonstrating material model dependence in the smaller population. A parameter-to-information ratio summarizes the burden on complete-outcome regressions within cross-fitting. Its simulation-calibrated warning level is 0.31 (0.28 - 0.35) for the original regime; additional simulations examine covariate-dependent censoring, delayed benefit and nonlinear misspecification. The ratio does not certify estimator validity or replace weight diagnostics. The contribution is a reproducible workflow that separates design, nuisance-model support and estimator stability before interpreting observational survival contrasts.
]]></description>
<dc:creator><![CDATA[ Fahmy, W., Krikun, E., Alkhateeb, A. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.29.26364358</dc:identifier>
<dc:title><![CDATA[Design and outcome-model estimability in doubly robust survival analysis: a breast cancer reanalysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.29.26364335v1?rss=1">
<title>
<![CDATA[
Methylation-associated Gene Expression (MaGE): a non-invasive, in vivo measure of cellular senescence. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.29.26364335v1?rss=1
</link>
<description><![CDATA[
Cellular senescence is a central hallmark of aging, yet its measurement in humans remains invasive, low-throughput and tissue-specific, precluding population-scale study. We developed Methylation-associated Gene Expression (MaGE) predictors: whole-blood DNA methylation proxies of p14ARF, p16INK4A and p21CIP1 expression, plus a composite score, providing the first scalable measure of senescence-marker expression. Deployed across Generation Scotland (n=18,859), MaGE yielded 45 Bonferroni-significant associations spanning 18 incident diseases and all-cause mortality. The two strongest associations recapitulated the established tissue specificity of p21CIP1 and p16INK4A activation, with MaGE-p21 associating with incident alcoholic liver disease and MaGE-p16 with pulmonary fibrosis. In a separate study, MaGE tracked disease severity and treatment response in Crohn's disease. MaGE is a scalable, interpretable biomarker of senescence that enables its study at population scale and offers a route to patient stratification in senolytic trials.
]]></description>
<dc:creator><![CDATA[ Simpson, D. J., Crofts, S. J., Mavrommatis, C., White, T. A., Suwanlikit, Y. J., Loyva, K., Rocca, W. A., Kantarci, K., Mielke, M., Richmond, A., Marioni, R. E., Kirschner, K., LeBrasseur, N. K., Chandra, T. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.29.26364335</dc:identifier>
<dc:title><![CDATA[Methylation-associated Gene Expression (MaGE): a non-invasive, in vivo measure of cellular senescence.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.30.26364374v1?rss=1">
<title>
<![CDATA[
Triangulating population, individual, and genetic evidence for priority setting in structurally heterogeneous blocs: metabolic risk factors for stroke in the Shanghai Cooperation Organisation 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.30.26364374v1?rss=1
</link>
<description><![CDATA[
BACKGROUND: Regional stroke-prevention priorities usually rest on what a bloc's members share. Where members span multiple Global Burden of Disease (GBD) super-regions and genetic ancestry groups, population, individual, and genetic evidence face different transportability limits, and earlier combined studies did not prespecify what counts as disagreement. METHODS: We studied the Shanghai Cooperation Organisation, which spans four super-regions and five ancestry groups and is land-contiguous. For five metabolic risk factors we triangulated GBD 2023 attributable fractions of stroke DALYs in ten states, incident stroke among 7896 adults in the China Health and Retirement Longitudinal Study (2011-18; SHRs per 1 SD), and subtype-specific Mendelian randomisation in three ancestries. An explicit rule set, with one pre-submission amendment, classified convergence and divergence by whether a listed mechanism accounted for it. FINDINGS: High systolic blood pressure converged: 53-71% of attributable DALYs, the strongest cohort exposure (SHR 1.37, 95% CI 1.26-1.48), and genetically supported in both ancestries. LDL cholesterol (GBD attribution restricted to ischaemic stroke; European genetic evidence for that subtype; no cohort association) and body-mass index (last in attribution but second in the cohort, with a 1.80-fold [1.48-2.18] gradient inside the 20-25 kg/m2 minimum-risk window) showed structural discordance. The cohort lacked subtype data to establish LDL dilution. Fasting glucose and kidney dysfunction diverged without such a mechanism. INTERPRETATION: Systolic blood pressure had the strongest cross-stream support. LDL cholesterol and body-mass index require qualified interpretation; fasting glucose and kidney dysfunction could not be ranked reliably. The framework identifies where priorities require scrutiny. FUNDING: None.
]]></description>
<dc:creator><![CDATA[ Wang, X., Li, M., Zhang, J., Zhang, H., Ma, Y. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.26364374</dc:identifier>
<dc:title><![CDATA[Triangulating population, individual, and genetic evidence for priority setting in structurally heterogeneous blocs: metabolic risk factors for stroke in the Shanghai Cooperation Organisation]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.25.26363797v1?rss=1">
<title>
<![CDATA[
Potential impact of changes in influenza vaccination coverage and effectiveness on pediatric influenza burden in the United States, 2022/23-2024/25 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.25.26363797v1?rss=1
</link>
<description><![CDATA[
Background and Objectives: Influenza vaccination has a strong safety record and is effective in reducing pediatric influenza-associated morbidity and mortality. However, pediatric vaccination coverage (VC) has declined since the 2019/20 influenza season in the United States. We estimated the impact of increased vaccine protection (through increased VC and/or vaccine effectiveness [VE]) on pediatric influenza-associated burden during the 2022/23-2024/25 seasons. Methods: We used a compartmental model and laboratory-confirmed influenza-associated hospitalization, VC, and VE data among children 6 months-17 years to estimate influenza burden from 2022/23-2024/25 (the 'baseline' scenario) and the impact of vaccination. We simulated scenarios that (1) increased VC by five percentage points; (2) increased VE by five percentage points; (3) increased VC and VE by five percentage points; and (4) increased VC to levels achieved in 2019/20 (the season with the highest pediatric VC to date). We estimated the difference in hospitalizations and deaths between each scenario and the baseline scenario. Results: Among children 6 months-17 years, an estimated 120,000 influenza-associated hospitalizations and 1,650 deaths occurred across all seasons at baseline. Increasing VC to 2019/20 levels had the greatest estimated impact, reducing hospitalizations by 8,670 (7.2%) and deaths by 130 (7.9%). Increasing both VC and VE by five percentage points reduced hospitalizations by 6.6% and deaths by 6.7%, whereas increasing VC or VE by five percentage points reduced hospitalizations by 3.1% and deaths by 3.2%. Conclusions: Increasing pediatric influenza vaccination coverage back to 2019/20 levels was estimated to significantly reduce pediatric influenza-associated morbidity and mortality.
]]></description>
<dc:creator><![CDATA[ Morris, S. E., Mathis, S. M., Chung, J. R., DeCuir, J., Olson, S. M., Ellington, S., O'Halloran, A., Ujamaa, D., Bozio, C. H., Jain, A., Srivastav, A., Lu, P.-j., Grohskopf, L. A., Reed, C., Iuliano, A. D., Biggerstaff, M. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.25.26363797</dc:identifier>
<dc:title><![CDATA[Potential impact of changes in influenza vaccination coverage and effectiveness on pediatric influenza burden in the United States, 2022/23-2024/25]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.29.26364351v1?rss=1">
<title>
<![CDATA[
Occupational endotoxin exposure, DNA methylation changes, and immune-cell remodeling: an epigenome-wide association study in two cohorts 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.29.26364351v1?rss=1
</link>
<description><![CDATA[
Background: Millions of textile and agricultural workers inhale organic dust containing endotoxin, an exposure associated with impaired respiratory function. However, the underlying biological pathways remain unclear. We conducted a two-cohort epigenome-wide association study (EWAS) to identify airborne endotoxin-associated DNA methylation (DNAm) alterations and pathways. Methods: In the discovery phase, we compared blood DNAm in 281 endotoxin-exposed cotton workers and 253 unexposed silk-workers from the Shanghai Textile Worker Study (STWS) measured using Illumina MethylationEPICv2 arrays. STWS endotoxin assessment combined detailed work histories and onsite measurements. For targeted parallel validation, we tested STWS signals in 686 incident lung cancer cases and 683 matched controls from the Shanghai Women's Health Study (SWHS), using occupation-derived low, medium, or high exposure-intensity ranks based on published evidence. To gain biological insight, we analyzed pathway enrichment, immune-cell composition, DNAm inflammation risk scores (IRSs), and respiratory phenotype associations in STWS. Results: In STWS, we identified 36 epigenome-wide significant DNAm sites (P<5e-8), of which, 35 were hypomethylated. Among 30 sites testable in SWHS, 18 had concordant effect directions, and four were nominally significant: cg11869499 (POLG; P=0.041), cg16290931 (TSKS; P=0.044), cg05019530 (EPIC1; P=0.042), and cg26033526 (PSMB9/TAP1; P=0.013). Enrichment implicated immune and signal-transduction pathways, including IgSF cell-adhesion-molecule signaling (FDR=8.2e-6;). Neutrophil were higher in cotton workers than in silk workers (63.5% vs 58.9%, p=7.52e-10). Cumulative endotoxin was associated with higher CRP-based IRSs, which showed the most consistent associations with lower lung function and airflow obstruction. Conclusions: Our EWAS findings suggest that occupational endotoxin may operate partly through immune-cell composition and inflammatory pathways.
]]></description>
<dc:creator><![CDATA[ Wang, H., Rahman, M. L., Breeze, C. E., Lim, J., Hu, W., Zhang, F., Cai, Q., Yang, G., Long, J., Su, L., Gao, Y.-T., Shu, X.-o., Blechter, B., Shi, J., Rothman, N., Zheng, W., Lan, Q., Christiani, D. C., Wong, J. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.29.26364351</dc:identifier>
<dc:title><![CDATA[Occupational endotoxin exposure, DNA methylation changes, and immune-cell remodeling: an epigenome-wide association study in two cohorts]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.25.26364016v1?rss=1">
<title>
<![CDATA[
Age-Stratified Patterns of Diagnostic Delay in Pertussis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.25.26364016v1?rss=1
</link>
<description><![CDATA[
Background: Pertussis has resurged in the post-COVID-19 era, yet diagnostic delay remains a barrier to timely treatment and transmission interruption, particularly among adults. Methods: Retrospective observational cohort study of 787 patients with confirmed pertussis from January 2016 through March 2026 across two South Carolina health systems. Electronic health record data from the 60 days preceding confirmation were used to characterize diagnostic timing (same-day vs. delayed), delay duration, and respiratory pathogen testing patterns including pertussis test modality. Results: Adults accounted for 48.4% of cases (median age 16 years [IQR 4-52]; 61.6% female). Same-day diagnosis was highest among children aged 1-4 years (75.4%) and lowest among adults aged 50 and older (approximately 50%). Among the 305 patients (38.8%) with delayed diagnosis, median delay ranged from 7-12 days in children to 22.5-26.5 days in adults aged 50 and older. Delay did not vary significantly by COVID-19 period, race, ethnicity, or insurance type. Testing breadth was greater in inpatient and emergency settings than outpatient. Pertussis testing was predominantly PCR-based in children but serologic in adults, potentially reflecting later clinical presentation relative to illness onset; however, the near-absence of PCR testing in older adults may contribute to missed diagnoses during the early illness window when PCR sensitivity is highest. Conclusions: Older adults experienced markedly delayed pertussis diagnoses compared with children. Earlier consideration of pertussis in adults with prolonged cough, including PCR testing early in illness before serologic conversion, may reduce diagnostic delay and facilitate timelier treatment and contact tracing.
]]></description>
<dc:creator><![CDATA[ Serman, E. A., Jayawardena, I., Liskey, C., LaCroix, R., Litwin, A. H., Obeid, J. S., Curry, S. R., Rennert, L. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.25.26364016</dc:identifier>
<dc:title><![CDATA[Age-Stratified Patterns of Diagnostic Delay in Pertussis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.29.26364034v1?rss=1">
<title>
<![CDATA[
Associations of Outdoor Air Pollution With Cause-specific Mortality in Metastatic Prostate Cancer: A cohort study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.29.26364034v1?rss=1
</link>
<description><![CDATA[
Background: Cardiovascular disease is an important competing cause of death in men with metastatic prostate cancer, and ambient air pollution may increase cardiovascular vulnerability. We evaluated associations of fine particulate matter (PM2.5) and nitrogen dioxide (NO2) with all-cause, cardiovascular, and prostate cancer-specific mortality, including joint associations with androgen deprivation therapy (ADT). Methods: We analyzed 33,384 men from 11 US state registries diagnosed with metastatic prostate cancer during 2000-2015 and followed through 2018. Residential PM2.5 and NO2 concentrations at diagnosis were assigned using 1-km exposure models. Multivariable Cox models estimated all-cause mortality, and inverse-probability-weighted Cox models assessed cause-specific mortality. Results: Each interquartile-range increase in PM2.5 was associated with higher cardiovascular mortality (HR 1.04, 95% CI 1.02-1.07; p-trend=0.008). Cardiovascular mortality was also higher in the fourth and fifth PM2.5 quintiles versus the first (HR 1.18 and 1.21, respectively). Higher NO2 was associated with prostate cancer-specific mortality in the highest quintile (HR 1.07, 95% CI 1.01-1.13). In joint analyses, ADT-treated men with high versus low PM2.5 exposure had higher cardiovascular mortality (HR 1.19, 95% CI 1.05-1.34), without clear evidence of effect modification (p-interaction=0.051). Conclusions: In men with metastatic prostate cancer, higher PM2.5 exposure was associated with cardiovascular mortality, particularly among ADT-treated patients, supporting further study of environmental exposures and systemic therapy in cardio-oncology.
]]></description>
<dc:creator><![CDATA[ Cosenza, A., Nguyen, D.-D., Qian, Z., Striano, V., Appleman, L., Montorsi, F., Briganti, A., Gandaglia, G., Davies, B. J., Jacobs, B. L., Trinh, Q.-D., Iyer, H. S. ]]></dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.29.26364034</dc:identifier>
<dc:title><![CDATA[Associations of Outdoor Air Pollution With Cause-specific Mortality in Metastatic Prostate Cancer: A cohort study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.27.26364122v1?rss=1">
<title>
<![CDATA[
Selection without Collider Stratification can Bias Instrumental Variable Analyses in the Presence of Causal Effect Heterogeneity 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.27.26364122v1?rss=1
</link>
<description><![CDATA[
Selection bias is a common concern in causal inference. Two mechanisms can give rise to selection bias: collider bias or stratifying on an effect modifier of the exposure-outcome causal effect. Research into the impact of selection bias on instrumental variable (IV) analyses has focused primarily on collider bias. Here, we show that IV estimates can be biased if selection is an effect modifier (or caused by an effect modifier) of the exposure-outcome effect. In a simulation study, we investigate the size and direction of the bias when estimating effects on the mean difference or odds ratio scale. Bias can also occur due to heterogeneity in the instrument-exposure relationship, although its magnitude is typically smaller. Finally, we discuss methods to deal with this bias in practice, including inverse probability weighting (IPW).
]]></description>
<dc:creator><![CDATA[ Gkatzionis, A., Hartwig, F. P., Tilling, K. ]]></dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.27.26364122</dc:identifier>
<dc:title><![CDATA[Selection without Collider Stratification can Bias Instrumental Variable Analyses in the Presence of Causal Effect Heterogeneity]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.29.26364168v1?rss=1">
<title>
<![CDATA[
Endometriosis and Cardiovascular Disease Across Levels of Systemic Inflammation: A Cross-Sectional Study of NHANES 1999-2006 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.29.26364168v1?rss=1
</link>
<description><![CDATA[
Background: Endometriosis is a chronic gynecologic condition which has been linked with higher cardiovascular disease (CVD) risk. Although systemic inflammation is central to endometriosis and CVD pathophysiology, it remains unclear whether endometriosis is associated specifically with early-onset CVD and whether systemic inflammation modifies this association. Methods: This was a cross-sectional study of 5,345 women aged 20-54 years from the National Health and Nutrition Examination Survey (1999-2006). Endometriosis and early-onset CVD were self-reported. Early-onset CVD was defined as a composite measure of coronary heart disease, angina/angina pectoris, heart attack, congestive heart failure, or stroke. Systemic inflammation was measured using C-reactive protein [CRP; low/moderate ([&le;] 3 mg/L) and high (>3mg/L)] and the systemic immune-inflammation index (SII; tertiles). Survey-weighted logistic regression was used to assess associations and heterogeneity by systemic inflammation, with stabilized inverse probability weighting (IPW) to adjust for confounding. Results: Of the 5,435 women, 370 (6.9%) reported an endometriosis diagnosis and 162 (3.0%) early-onset CVD. After IPW adjustment for age, body mass index, smoking status, education, age at menarche, physical activity and race/ethnicity, endometriosis was associated with higher odds of early-onset CVD (prevalence odds ratio [POR] = 1.91, 95% CI: 1.23-2.97). This association was strongest among women with high CRP (POR= 2.33, 95% CI: 1.49-3.66), but not among those with low/moderate CRP levels (p-interaction= 0.086). Across SII strata, the strongest association was observed among women in the medium SII tertile (POR = 2.92, 95% CI: 1.47-5.78), with no associations in the low or high tertiles (p-interaction = 0.288). Conclusion: Endometriosis was associated with higher odds of early-onset CVD in this nationally representative sample of U.S. women. Although the strength of the association varied across CRP and SII strata, formal tests for interaction were not statistically significant. These findings should be understood as exploratory and require further investigation in prospective studies
]]></description>
<dc:creator><![CDATA[ Oli, C., Chichetto, N. ]]></dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.29.26364168</dc:identifier>
<dc:title><![CDATA[Endometriosis and Cardiovascular Disease Across Levels of Systemic Inflammation: A Cross-Sectional Study of NHANES 1999-2006]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.29.26364286v1?rss=1">
<title>
<![CDATA[
Comparing epigenetic puberty and epigenetic clocks as biomarkers of adult biological aging and health 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.29.26364286v1?rss=1
</link>
<description><![CDATA[
Recent lifespan frameworks of aging theorize that pubertal development and cellular aging are governed by overlapping pathways, but the time lag between adolescence and older adulthood complicates the study of shared molecular mechanisms. Here we compare a DNA-methylation-based epigenetic index of pubertal development to epigenetic clocks, which were designed to measure biological aging, as a putative biomarker of adult aging and health in two adult cohorts: 3,642 older Americans in the Health and Retirement Study (HRS; age range, 56 to 100 years; 2,106 females) and 18,676 adults from Generation Scotland (GS; age range, 18 to 98 years; 10,974 females). Epigenetic puberty was correlated with chronological age in both cohorts, moderately in the older HRS sample (r = 0.51 in females, r = 0.51 in males) and strongly across the wider adult age range of GS (r = 0.82 in females, r = 0.86 in males). In both cohorts, age-residualized epigenetic puberty was associated with accelerated biological aging as measured by epigenetic clocks and other aging biomarkers (standardized coefficients: HRS, 0.13 to 0.47, all P < 0.005; GS, 0.05 to 0.40, all P < 0.001). Epigenetic puberty was linked with multiple health outcomes: mortality in HRS in both sexes (ORs, 1.39 and 1.46, both P [&le;] 0.001) and in GS among females (HR, 1.12, P = 0.003); 10-year onset of diabetes, any cancer and lung disease in GS (HRs, 1.12 to 1.19, all P < 0.005); and with multimorbidity, functional limitations and BMI in females in HRS (standardized coefficients, 0.10 to 0.16, all P < 0.001). It also accounted for a unique, albeit smaller, proportion of variance in aging-related outcomes beyond that explained by epigenetic clocks. These findings indicate that the epigenetic puberty index reflects pro-aging underlying biology, showing overlapping molecular pathways between pubertal development and cellular aging, and support a lifespan-based approach to studying biological aging.
]]></description>
<dc:creator><![CDATA[ Wu, Q., Gibbs, S. F. P., deSteiguer, A. J., Zarandooz, S., Willems, Y. E., Smith, T., Goode, J. A., Mitchell, C., Crimmins, E. M., Harden, K. P., Marioni, R. E., Raffington, L. ]]></dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.29.26364286</dc:identifier>
<dc:title><![CDATA[Comparing epigenetic puberty and epigenetic clocks as biomarkers of adult biological aging and health]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.29.26364336v1?rss=1">
<title>
<![CDATA[
Delayed Coal Plant Retirements in the Era of Data Centers Carry a Measurable Mortality Cost 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.29.26364336v1?rss=1
</link>
<description><![CDATA[
Coal-fired power plants remain a major source of fine particulate matter (PM2.5) exposure and mortality in the United States. Announced retirement dates mark when those burdens are expected to end, but rising electricity demand, partly from data centers supporting cloud computing and artificial intelligence, has led utilities and regulators to revisit them. Of 50 coal plants scheduled in January 2024 to retire before 2035, 20 had later or removed dates by January 2026. Projecting coal PM2.5 and mortality among Medicare beneficiaries from the 20 plants for 2026-2035, we estimate the revised schedule would result in 1,256 additional deaths (1,136 to 1,376), raising mortality to 3.1 times the original burden. Eighteen plants operate in balancing authorities with hyperscale data-center demand, and federal orders and utility filings supporting several plants' operation cited data-center growth. Retirement schedules are revised faster than health consequences are assessed, and those delays carry a measurable mortality cost.
]]></description>
<dc:creator><![CDATA[ Bong, S., Gianluca, G., Cork, M., Henneman, L. R., Dominici, F. ]]></dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.29.26364336</dc:identifier>
<dc:title><![CDATA[Delayed Coal Plant Retirements in the Era of Data Centers Carry a Measurable Mortality Cost]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.23.26363799v1?rss=1">
<title>
<![CDATA[
Incidence and determinants of antibiotic use by age two: a prospective cohort study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.23.26363799v1?rss=1
</link>
<description><![CDATA[
Background: Half of US children are prescribed an antibiotic by age 2. Maternal education and socio-economic factors influence prescribing but the role of other factors, such as age of solid food introduction is unknown. Objectives: We assessed risk factors for time to first antibiotic use between birth to age 2 to identify modifiable drivers of antibiotic use. Methods: We analyzed interviews from mothers of 1032 children participating in the mother-child Center for Oral Health Research in Appalachia cohort 2 between 2011 and 2017. The cohort enrolled healthy, English-speaking, pregnant White women > 18 years with singleton pregnancies. We used time-to-event analyses and a Cox Proportional Hazards model to describe and estimate hazard ratios (HRs) for time to first antibiotic. Results: By age 2, 78% of children received at least one antibiotic (median age at first antibiotic: 12.5 months). Over half (58%) of antibiotics prescribed were for ear infections. After adjustment for household income and birth quarter as fixed variables, time of solid food introduction (aHR: 4.75; 95% CI: 3.19, 7.07), time of first ear infection (aHR: 3.28; 95% CI: 2.58,4.17), and time of first illness (aHR: 4.60; 95% CI: 3.32,6.36) were significantly associated with time of first antibiotic use. Conclusions: Earlier time of solid food introduction was associated with earlier antibiotic use. Childhood illnesses, especially ear infections, also strongly influence antibiotic initiation. These modifiable factors offer targets to reduce unnecessary early antibiotic use.
]]></description>
<dc:creator><![CDATA[ Staal, A., Zhen, H., Zhang, T., Byrd, M. C., Kamdar, N., Shaffer, J. R., McNeil, D. W., Marazita, M., Foxman, B. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.26363799</dc:identifier>
<dc:title><![CDATA[Incidence and determinants of antibiotic use by age two: a prospective cohort study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.23.26363787v1?rss=1">
<title>
<![CDATA[
Daily Exceedance of World Health Organization Air Pollutant Guidelines and Cognitive Aging 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.23.26363787v1?rss=1
</link>
<description><![CDATA[
ImportanceLong-term exposure to higher average air pollutant concentrations is associated with poorer cognitive health, but annual averages can obscure substantial differences in day-to-day exposure. Whether recurrent high pollution days are associated with long-term cognitive aging trajectories among people with similar overall air pollution exposure is unclear.

ObjectiveTo determine whether the annual number of days exceeding World Health Organization daily guideline values for nitrogen dioxide (NO2) and particulate matter (PM2.5 and PM10) is associated with subsequent cognitive decline after accounting for annual mean air pollutant exposure.

DesignProspective cohort study using data from waves 1-10 (2002-03 to 2021-23) of the English Longitudinal Study of Ageing.

SettingPopulation-based cohort of community-dwelling adults in England.

Participants12,235 adults aged 50+ years at analytic baseline.

ExposuresNumber of days exceeding World Health Organization daily guideline values ( exceedance days) for NO2, PM2.5, and PM10, derived from residence-linked environmental estimates during the calendar year preceding the analytic baseline.

Main Outcomes and MeasuresBaseline cognitive performance and model-estimated 14- year cognitive decline (corresponding to the 75th percentile of follow-up duration) in episodic memory and verbal fluency.

ResultsExceedance days were not associated with baseline memory or verbal fluency after adjustment for annual mean air pollutant exposure. More NO2 exceedance days were associated with faster cognitive decline: comparing the 75th percentile with the median of NO2 exceedance days, the difference in 14-year decline was -0.09 SD (95% CI, -0.17 to -0.01; p = 0.02) for memory and -0.10 SD (95% CI, -0.19 to 0.00; p = 0.04) for fluency. PM2.5 and PM10 exceedance days were not associated with cognitive decline.

Conclusions and RelevanceIn this cohort study of older adults, a higher number of NO2 exceedance days was associated with faster subsequent cognitive decline after adjustment for annual mean air pollutant exposure. This suggests that daily exposure to high NO2 concentrations may be related to accelerated cognitive aging even when offset by lower exposure on other days, potentially providing a new rationale for identifying and prioritizing areas with recurrent high NO2 exposure and the local emission sources contributing to it.

Key pointsO_ST_ABSQuestionC_ST_ABSAmong individuals with similar average air pollution exposure but different day-to-day exposure patterns, are more high pollution days associated with faster cognitive decline?

FindingsIn this UK-based cohort of 12,235 adults aged 50+, individuals exposed to more days on which nitrogen dioxide (NO2) concentrations exceeded World Health Organization guideline values subsequently had significantly faster cognitive decline over up to 18 years, after adjustment for annual mean air pollutant exposure. No associations were observed for particulate matter.

MeaningDaily exposure to high NO2 concentrations is associated with faster cognitive decline even when offset by lower concentrations on other days.
]]></description>
<dc:creator><![CDATA[ Bloomberg, M., Di Gessa, G., Scholes, S., Gasparrini, A., de la Cruz Libardi, A., Steptoe, A., Zaninotto, P. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.26363787</dc:identifier>
<dc:title><![CDATA[Daily Exceedance of World Health Organization Air Pollutant Guidelines and Cognitive Aging]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.28.26364210v1?rss=1">
<title>
<![CDATA[
Gendered behaviors are associated with health beyond binary sex 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.28.26364210v1?rss=1
</link>
<description><![CDATA[
Sex and gender are distinct but intertwined determinants of health. Both adherence to and deviation from gender norms carry consequences for health, yet genders contribution to disease risk beyond binary sex remains largely unexplored. As gender is organized around sex from its developmental origins, masculine and feminine health behaviors can be defined by how males and females behave collectively. Individuals vary in how closely they align with these norms, defining a biopsychosocial gender spectrum. Here, we used machine learning to reconstruct population-specific masculine and feminine behavioral norms, yielding a continuous Index of Gendered Life-domains (IGL) in 301,113 UK Biobank participants. In sex-stratified analyses of body and brain health phenotypes, masculine behavioral profiles were associated with greater physiological load and cardiometabolic disease risk, and feminine profiles with higher trait anxiety and musculoskeletal vulnerability. Sex-IGL incongruence predicted state-like psychiatric symptoms and severe mental health diagnoses. An intersectional approach revealed differences in gendered behaviors and their health associations across ethnic groups, demonstrating that gender measurement must be sensitive to sociocultural context to characterize health risk in diverse populations. These findings establish gender as a socioculturally embedded determinant of health whose health associations go beyond binary sex.
]]></description>
<dc:creator><![CDATA[ Parent, O., McGuinness, M., Osborne, S., Danyluik, M., Mukora, A. W., Quesada, D., Devenyi, G. A., Raznahan, A., Juster, R. P., Dadar, M., Chakravarty, M. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.26364210</dc:identifier>
<dc:title><![CDATA[Gendered behaviors are associated with health beyond binary sex]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.23.26363802v1?rss=1">
<title>
<![CDATA[
Surrogate methods for parameter inference in transmission dynamic models 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.23.26363802v1?rss=1
</link>
<description><![CDATA[
Mechanistic models of infectious disease transmission provide a framework for understanding and predicting disease dynamics, but statistical inference is often computationally prohibitive. This challenge is especially pronounced for models with high-dimensional structures and many unknown parameters, where trajectory matching may require thousands of evaluations of an expensive likelihood function. We developed a surrogate-assisted optimization framework that uses Bayesian optimization to reduce the number of evaluations of the underlying mechanistic model required for parameter inference. We evaluated the approach using simulated fitting problems based on age-structured susceptible-exposed-infected-recovered models with 4, 8, and 16 age classes and a 210-compartment age-structured rotavirus transmission model. Applying surrogate-assisted optimization substantially reduced the number of likelihood evaluations required to identify good parameter estimates, with larger improvements as model dimensionality increased. In the rotavirus model, the surrogate Bayesian optimization approach reached the benchmark after approximately 0.7 hours, compared with approximately 9.4 hours using traditional Nelder-Mead optimization. These results demonstrate that surrogate-assisted optimization can substantially reduce the computational burden of trajectory matching for complex mechanistic transmission models, particularly for higher-dimensional inference problems.
]]></description>
<dc:creator><![CDATA[ Lee, P. C., Huang, K., Tartof, S. Y., Rodriguez-Barraquer, I., Müller, N. F., Schuler, A., Lewnard, J. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.26363802</dc:identifier>
<dc:title><![CDATA[Surrogate methods for parameter inference in transmission dynamic models]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.23.26363728v1?rss=1">
<title>
<![CDATA[
No Field for Lactation: Inferring Lactation Status From US Commercial Claims to Describe Postpartum Medication Dispensing 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.23.26363728v1?rss=1
</link>
<description><![CDATA[
PurposeLactation status is not recorded as a discrete data element in U.S. administrative claims databases, limiting research on lactation in health databases. We developed a claims-based phenotype to identify periods of probable lactation and used it to describe medications dispensed to lactating women enrolled in a national health plan.

MethodsThis retrospective cohort study used data from the 2012-2014 Merative MarketScan Commercial Claims Database. Deliveries were identified by diagnosis-related group classification system. Lactation windows ran from the delivery date to the date of the last surrogate lactation indicator, such as breast pump and supply codes, the encounter code for supervision of a lactating mother, and mastitis. New prescriptions filled within a window were characterized by therapeutic group, prescriber type, lactation risk category, and availability of published lactation data.

ResultsOf 566,284 women with a single delivery, 84,679 were determined to be lactating using the developed algorithm based on maternal phenotype. The median length of assignable lactation window was 17 days (IQR 5-47). Windows most often closed on a breast pump claim (53.2%) or a postpartum visit code (28.2%). Among 158,471 new prescriptions filled during lactation, central nervous system agents (54.5%), anti-infectives (17.5%), and hormonal products accounted for > 80%. Combined oral contraceptives represented 8.2% of hormonal prescriptions during lactation against 29.0% among women of unknown status. Obstetricians wrote approximately one third of prescriptions filled during lactation windows.

ConclusionsLactation can be identified in administrative claims using codes already present in the data, making national description of dispensing during lactation possible.
]]></description>
<dc:creator><![CDATA[ Krutsch, K., Appiah, D. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.26363728</dc:identifier>
<dc:title><![CDATA[No Field for Lactation: Inferring Lactation Status From US Commercial Claims to Describe Postpartum Medication Dispensing]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.28.26363311v1?rss=1">
<title>
<![CDATA[
Epigenetic Exposure Signatures Distinguish Early-Onset from Later-Onset Colorectal Cancer in a Racially Diverse US Cohort: Findings from the Disparities and Cancer Epidemiology (DANCE) Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.28.26363311v1?rss=1
</link>
<description><![CDATA[
Background: The incidence of early-onset colorectal cancer (EOCRC), defined as CRC diagnosed age <50, is rising in the United States and is the leading cause of cancer death in among those with early-onset cancer. Epigenetic exposure signatures based on methylation risk scores (MRS) offer a novel approach to identify long-term exposures that may contribute to EOCRC risk. We sought to replicate findings from a recent study in a racially and geographically diverse CRC cohort. Methods: We computed weighted MRS across lifestyle, air pollution, and pesticide exposome traits in 146 participants from the Disparities and Cancer Epidemiology (DANCE) cohort, a diverse population-based CRC study, applying the Maas et al. (2026) framework to tumor tissue. Associations between MRS and age at CRC onset (EOCRC, n=29; intermediate-onset (IOCRC) 50-64 years, n=69; late-onset, [&ge;]65 years, n=48) were evaluated using linear and polytomous regression, with adjustment and stratification for race, geography, Area Deprivation Index (ADI), and Multi-Environmental Exposure Index (MEEI). Spearman correlations were calculated between MRSes and observed exposures. Results: EOCRC cases were predominately Black (65.5% vs. 31.3% among LOCRC) and resided in higher-deprivation neighborhoods. We found higher odds of EOCRC associated with epigenetic exposure signatures for 2,4-D herbicide, heptachlor, coarse particulate matter (PM), Mediterranean Diet Score, and smoking, and borderline associations for fine PM and nitrogen dioxide. IOCRC was associated with signatures for 2,4-D, lindane, and obesity. Heterogeneity was observed by race and area-level factors, though associations were largely consistent across strata. ADI and MEEI were correlated with multiple pesticide and pollutant epigenetic signatures. Conclusions: In a diverse US cohort, epigenetic exposure signatures distinguish CRC cohorts, particularly EOCRC from later-onset disease, with associations consistent with but not identical to previous research. EOCRC in DANCE was characterized by higher epigenetic exposure signatures for air pollution, smoking, and distinct pesticide exposure profiles. IOCRC had overlapping characteristics with early- and late-onset and were the only group with a significant obesity signature. These findings support the hypothesis that exposome-driven epigenetic changes contribute to EOCRC risk and highlight the importance of studying diverse populations to characterize the full spectrum of environmental risk factors.
]]></description>
<dc:creator><![CDATA[ Lima, S. M., Ahn, J., Dash, C., Hseih, M.-C., Jones, R. R., Mabvakure, B. M., Muhsen, R., Patil, S., Peluso, A., Promprasert, C., Qin, T., Ruterbusch, J. R., Sartor, M. A., Schwartz, A. G., Wenzlaff, A. S., Zhang, R., Stoffel, E. M., Purrington, K. S., Rozek, L. S. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.26363311</dc:identifier>
<dc:title><![CDATA[Epigenetic Exposure Signatures Distinguish Early-Onset from Later-Onset Colorectal Cancer in a Racially Diverse US Cohort: Findings from the Disparities and Cancer Epidemiology (DANCE) Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.28.26364207v1?rss=1">
<title>
<![CDATA[
Trends in transitions in cigarette and electronic nicotine vapor product use in the Rutgers Omnibus Study, 2022-2026 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.28.26364207v1?rss=1
</link>
<description><![CDATA[
Introduction: Monitoring transitions in cigarette and electronic nicotine vapor product (ENVP) use is important for understanding how marketplace and regulatory changes have affected product use patterns, but information from national surveys is often delayed by several years. Methods: The Rutgers Omnibus Study is a quarterly serial, rapid-response, web-based convenience survey. Using a Markov multistate transition model, we estimated transition rates and one-year transition probabilities between never, non-current, ENVP-only, cigarette-only, and dual use among 5,292 adults aged 18-45 who participated in at least two of Waves 1-16 (February 2022-February 2026), as well as overall transition hazard ratios by sex, age group, and race & ethnicity in a multivariable model. Results: About 40% of individuals using cigarettes (39.5%; 95% CI: 36.9-42.0) or ENVP (40.1%; 95% CI: 36.4-43.7), and 60% of those using both products (60.8%; 95% CI: 58.3-63.2) were predicted to remain in those states after one year. Female participants began using cigarettes from never use (adjusted hazard ratio [aHR] 0.44; 95% CI: 0.29-0.66) or non-current use (aHR 0.65; 95% CI: 0.48-0.88) at lower rates than male participants. Participants aged 35-45 years initiated ENVP-only use from non-current use (aHR 0.34; 95% CI: 0.23-0.51) at a lower rate than those aged 18-34 years. Compared to non-Hispanic White participants, non-Hispanic Black participants initiated ENVP-only use from never use at a higher rate (aHR 4.39; 95% CI: 2.09-9.25). Conclusion: Rapid response surveys can provide important preliminary information on tobacco use transition patterns while we wait for the slower release of nationally representative survey data.
]]></description>
<dc:creator><![CDATA[ Roberts, O. K., Bover Manderski, M. T., Gonsalves, N. J., Jeon, J., Meza, R., Delnevo, C. D., Brouwer, A. F. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.26364207</dc:identifier>
<dc:title><![CDATA[Trends in transitions in cigarette and electronic nicotine vapor product use in the Rutgers Omnibus Study, 2022-2026]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.28.26364183v1?rss=1">
<title>
<![CDATA[
Cancer epidemiology and survival in a high HIV prevalence region of Kenya: a 10-year retrospective cohort study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.28.26364183v1?rss=1
</link>
<description><![CDATA[
BackgroundCancer incidence and mortality are rising in Africa, yet the distribution and determinants of cancer in high HIV-prevalence regions remain limited. We characterized cancer epidemiology, treatment, and survival among adults in western Kenya, where HIV prevalence ranges between 10.3% and 11.7%.

MethodsThis retrospective cohort study included adults ([&ge;]18 years) with cancer treated at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) in Kisumu, Kenya, between Jan 1, 2014, and Dec 31, 2024, followed through June 30, 2025. Data were abstracted from paper records into REDCap. Negative binomial models estimated annual trends, Kaplan-Meier curves evaluated survival, and Cox proportional hazards models evaluated mortality

FindingsAmong 3978 patients (64% female; median age 53.9 years, IQR (42.0, 65.1), annual case counts rose from 29 to 708, averaging a 38% annual increase (95% CI 29-48). Cervical (24%), esophageal (13.6%), breast (12%), prostate (8%), and colorectal (4%) cancers accounted for 62% of cases. 1305 (33%) of cancer patients were living with HIV and 802 (20%) had unknown HIV status. Among patients whose cancer was assigned a stage, 72% presented at stage III-IV. 1973 (50%) received cancer-directed treatment, and 51% had an unscheduled clinic visit lapse of at least 180 days. Cancer-directed treatment was the strongest protective factor for mortality (adjusted hazard ratio [aHR] 0{middle dot}27, 95% CI 0{middle dot}22-0{middle dot}32); HIV-positive status (aHR 1{middle dot}43, 1{middle dot}19-1{middle dot}71), HIV-unknown status (aHR 1{middle dot}48, 1{middle dot}20-1{middle dot}81), and poor or missing performance status were independently associated with higher mortality, robust across sensitivity analyses.

InterpretationCancer mortality was strongly associated with treatment and HIV status at diagnosis. Closing the treatment-access gap and adopting routine opt-out HIV testing at the first oncology visit are essential for integrated cancer care in high-HIV-prevalence settings.

FundingResearch reported in this publication was supported by the American Cancer Society; the Washington University in St. Louis Institute of Clinical and Translational Sciences through a grant from the National Center for Advancing Translational Sciences (NCATs) of the National Institutes of Health; Just-in-Time funding, and the National Cancer Institute Center Support Grant P30CA091842.
]]></description>
<dc:creator><![CDATA[ Mangale, D., Adhiambo, H., Adagi, P., Atieno, D., Bowe, B., Wafula, C., McLigeyo, A., Odeny, T. A. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.26364183</dc:identifier>
<dc:title><![CDATA[Cancer epidemiology and survival in a high HIV prevalence region of Kenya: a 10-year retrospective cohort study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.28.26364179v1?rss=1">
<title>
<![CDATA[
Open ecological, genomic and digital behavioural data resolve the 2026 MV Hondius Andes virus outbreak to the southern-Andean reservoir zone 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.28.26364179v1?rss=1
</link>
<description><![CDATA[
The 2026 Andes virus (ANDV) outbreak aboard the MV Hondius cruise ship resulted in 11 confirmed cases and 3 deaths and raised questions regarding the origin of infection, with much media focus resting on a landfill in Tierra del Fuego. We evaluated competing exposure hypotheses by assembling open data on reservoir host occurrences, rodent serosurveys, and historical ANDV outbreaks along with the index cases self-documented, publicly-posted citizen-science digital record of their movements. Historical outbreaks associated with human-to-human transmission were concentrated within a restricted region spanning southern Chile and adjacent western Argentina, coinciding with the distribution of the principal reservoir host, Oligoryzomys longicaudatus, and areas identified as elevated risk by multiple ecological and genetic models. The index case was documented within this transmission focus shortly before the putative exposure period. Together, our open data approach was able to rapidly locate initial exposure within the established ANDV transmission focus and develop scenarios to prioritise further epidemiological investigation.
]]></description>
<dc:creator><![CDATA[ Redding, D., Albaladejo-Robles, G., Nino Barreat, J. G., Abbate, J., Simons, D. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.26364179</dc:identifier>
<dc:title><![CDATA[Open ecological, genomic and digital behavioural data resolve the 2026 MV Hondius Andes virus outbreak to the southern-Andean reservoir zone]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
